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Animal studies with Streptococcus pneumoniae have provided valuable models for drug development. In order
to monitor long-term pneumococcal infections noninvasively in living mice, a novel gram-positive lux trans-
poson cassette, Tn4001 luxABCDE Kmr, that allows random integration of lux genes onto the bacterial
chromosome was constructed. The cassette was designed so that the luxABCDE and kanamycin resistance
genes were linked to form a single promoterless operon. Bioluminescence and kanamycin resistance only occur
in a bacterial cell if this operon has transposed downstream of a promoter on the bacterium’s chromosome. S.
pneumoniae D39 was transformed with plasmid pAUL-A Tn4001 luxABCDE Kmr, and a number of highly
bioluminescent colonies were recovered. Genomic DNA from the brightest D39 strain was used to transform
a number of clinical S. pneumoniae isolates, and several of these strains were tested in animal models, including
a pneumococcal lung infection model. Strong bioluminescent signals were seen in the lungs of the animals
containing these pneumococci, allowing the course and antibiotic treatment of the infections to be readily
monitored in real time in the living animals. Recovery of the bacteria from the animals showed that the
bioluminescent signal corresponded to the number of CFU and that the lux construct was highly stable even
after several days in vivo. We believe that this lux transposon will greatly expand the ability to evaluate drug
efficacy against gram-positive bacteria in living animals using bioluminescence.
Streptococcus pneumoniae is the leading cause of invasive
bacterial disease in the very young and the elderly and is the
bacterium most responsible for community-acquired pneumo-
nia in the developed world (31). It can behave as a transient
commensal, colonizing the nasopharynx of 40% of healthy
adults and children, with no adverse effects (2). Children carry
this pathogen in the nasopharynx asymptomatically for about 4
to 6 weeks, often carrying several serotypes at a time (13, 33).
Occasionally, perhaps in conjunction with a viral infection (9),
one of these strains gives rise to a symptomatic pneumococcal
infection, including sinusitis, otitis media, pneumonia, and
meningitis (12, 13, 16).
Antibiotic treatment of pneumococcal infections has been
less effective in recent years with the increased occurrence of
multidrug-resistant strains of S. pneumoniae. About one-third
to one-half of pneumococci recovered from humans are at
least partially resistant to penicillin, which may occur in addi-
tion to resistance to a number of other common antibiotics (1,
3). These factors, plus the ability of the pneumococcus to
transfer genes for resistance, encapsulation, and virulence via
transformation (12), make it imperative to develop a better
understanding of the mechanism by which pneumococci cause
disease. Probably the best way to enhance this process is to
develop a better animal model.
In 1995, Contag et al. (7) showed that it was possible to
monitor disease processes in living animals using biolumines-
cence. These initial studies were conducted using the gram-
negative pathogen Salmonella enterica serovar Typhimurium
and demonstrated that bacterial growth and drug efficacy could
be monitored using this novel, noninvasive technology. Re-
cently, we have successfully modified and expressed the Pho-
torhabdus luminescence lux operon in gram-positive bacteria.
Broad-host-range shuttle vectors carrying this modified lux
operon were used to transform and monitor pathogenic strains
of Staphylococcus aureus in vivo in living animals using biolu-
minescence (11). Despite this achievement, animal studies
conducted with bioluminescent bacteria containing plasmid-
based lux constructs only allow short-term (,48 h) infections
to be accurately monitored in vivo in animals due to plasmid
loss in the absence of antibiotic selection. Thus, our objective
was to develop efficient methods of integrating the modified
luxABCDE operon into the chromosome of gram-positive bac-
teria, so that the bioluminescent signal would be stabilized and
more accurately reflect the number of viable bacterial cells
present in vivo in an animal.
In this article we describe the building of a gram-positive lux
transposon, Tn4001 luxABCDE Kmr, that can be used for sta-
ble bioluminescent transformation of a wide range of gram-
positive bacteria and show how this transposon was used to
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generate bioluminescent strains of S. pneumoniae. Using a
pneumococcal lung model, we demonstrate the advantages of
employing these bioluminescent strains to study S. pneumoniae
disease in live animals.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Escherichia coli strain DH5a was
obtained from Life Technologies (Rockville, Md.) and routinely grown at 37°C.
S. pneumoniae strain D39 was obtained from Tom Parr (Eli Lilly, Indianapolis,
Ind.). Clinical isolates of S. pneumoniae A66.1, HUSTMBIG, EF3030, and
140301 were obtained from Marc Lipsitch (Harvard School of Public Health,
Boston, Mass.) and David Briles (University of Alabama at Birmingham, Bir-
mingham, Ala.). All the S. pneumoniae strains were grown at 37°C in 5% CO2
unless otherwise stated.
Construction of gram-positive lux transposon plasmid pAUL-A Tn4001 lux-
ABCDE (Kmr). A diagram depicting the construction of the plasmid pAUL-A
Tn4001 luxABCDE (Kmr) is shown in Fig. 1. A P. luminescens lux operon
previously altered to be functional in gram-positive bacteria (11) was modified by
linking a promoterless gram-positive kanamycin resistance cassette downstream
of luxE. The kanamycin resistance gene was PCR amplified from pDL289 (4)
using primers KanF2 (59 CTG TAG ACT CGA GGA GGG AAA TAA TAA
ATG GC 39) and KanR2 (59 CAG AGT GTC GAC AGT TGC GGA TGT AC
39) (underlined sequences correspond to XhoI and SalI restriction enzyme sites
in KanF2 and KanR2, respectively, which were introduced to aid subsequent
cloning steps). PCR conditions for this and subsequent DNA amplifications were
those described previously by Francis et al. (11).
The amplified kanamycin resistance gene was digested with XhoI and SalI and
ligated into the SalI site of pBluescript II SK2 luxABCDE (11). The ligation was
electroporated into E. coli, spread onto Luria-Bertani (LB) agar containing
kanamycin (50 mg/ml), and incubated overnight at 37°C. Plates with kanamycin-
resistant colonies were screened for bioluminescence using a photon-counting
intensified-charge-coupled device (ICCD) camera (model 2400-32; Hamamatsu
Photonics, Bridgewater, N.J.). Plasmid DNA was isolated from bioluminescent,
kanamycin-resistant colonies using a standard alkaline lysis procedure (Plasmid
Spin Miniprep kit; Qiagen, Valencia, Calif.), as were all subsequent plasmid
isolations. These plasmids were then screened by PCR using the primers KanF2
and M13F (59 GTA AAA CGA CGG CCA GT 39), flanking the multiple cloning
site of pBluescript II SK2 (Strategene, La Jolla, Calif.), to identify constructs in
which the luxABCDE cassette was in the same orientation (59 to 39) as the
kanamycin resistance gene.
In order to construct a gram-positive lux transposon, the luxABCDE Kmr
cassette described above was moved from pBluescript SK2 luxABCDE Kmr into
pMGC57, a plasmid containing the Staphylococcus aureus transposon Tn4001
(21). pBluescript SK2 luxABCDE Kmr was cut with SpeI and SalI to remove the
luxABCDE Kmr cassette, and the DNA was blunt-end filled using T4 polymerase.
This blunt-end digest was then ligated with pMGC57 that had previously been
cut with EcoRV, a unique restriction site lying just inside the inner inverted
repeat sequence. The ligation reaction mix was electroporated into E. coli DH5a
and spread onto LB agar containing chloramphenicol (30 mg/ml) (pMGC57
contains a chloramphenicol resistance cassette), and the resulting colonies were
screened for bioluminescence using an ICCD camera. After confirming that the
bioluminescent, chloramphenicol-resistant colonies were also kanamycin resis-
tant by patching these colonies onto LB agar containing kanamycin (50 mg/ml),
plasmid DNAs were isolated from cultures of these clones as described above.
PCR was then conducted using primers MGC-CAT-F1 (59 GGT GTC CCT GTT
GAT ACC G 39) and LuxA-Rev (59 CCA CAC TCC TCA GAG ATG CG 39)
to identify which of the plasmids had the luxABCDE Kmr cassette in the correct
orientation in pMGC57 (i.e., the 59 end of luxA lying directly downstream of the
Tn4001 inner inverted repeat sequence; see Fig. 1).
To increase the efficiency of transposition in gram-positive bacteria, the above
Tn4001 luxABCDE Kmr cassette was moved onto the temperature-sensitive
gram-positive/negative shuttle vector pAUL-A (6). The Tn4001 luxABCDE Kmr
cassette was cut from pMGC57 using the enzymes EcoRI and XhoI and ligated
into the corresponding EcoRI and SalI sites of pAUL-A. The ligation was
electroporated into E. coli DH5a and spread onto LB agar containing erythro-
mycin (150 mg/ml) (pAUL-A contains an erythromycin resistance cassette), and
the resulting colonies were screened for bioluminescence using an ICCD camera.
After confirming that the bioluminescent, erythromycin-resistant colonies were
also kanamycin resistant, again by patching these colonies onto LB containing
kanamycin (50 mg/ml), plasmid DNAs were isolated as described above. These
plasmid DNAs were then used to transform S. pneumoniae strain D39.
Screening for stable, highly bioluminescent S. pneumoniae D39 Tn4001
luxABCDE transposants. The plasmid pAUL-A Tn4001 luxABCDE Kmr was
electroporated into S. pneumoniae D39 as described previously (18). The trans-
formation mix was plated on chocolate agar containing erythromycin (0.3 mg/ml),
and the plates were incubated for 24 to 48 h. Transformants of S. pneumoniae
D39 containing pAUL-A Tn4001 luxABCDE Kmr were patched onto chocolate
agar plates containing erythromycin (0.3 mg/ml) and incubated overnight. A
quantity of each patch (10-ml loopful of cell growth consisting of approximately
108 to 109 cells) was then uniformly streaked over the entire area of a chocolate
agar plate containing kanamycin (400 mg/ml) and incubated for 24 to 48 h.
Alternatively, S. pneumoniae D39 pAUL-A Tn4001 luxABCDE Kmr was cultured
overnight in 10 ml of brain heart infusion (BHI) containing erythromycin (0.3
mg/ml), pelleted, and resuspended in an equal volume of BHI, and 100-ml
volumes of a 10-fold dilution range (100 to 1028 in BHI) were spread onto a
chocolate agar plate routinely containing kanamycin (400 mg/ml) (up to 1,000
mg/ml in some instances) and incubated for 24 to 48 h. The resulting colonies
were screened for bioluminescence using an ICCD camera, and the brightest
were streaked onto chocolate agar plates containing kanamycin (400 mg/ml).
Single colonies were streaked subsequent times onto chocolate plates containing
no antibiotics to verify that bioluminescence was stable in the absence of anti-
biotic selection. Each strain was then graded for its level of bioluminescence
using an ICCD camera and Xenogen’s LivingImage software (Xenogen Corpo-
ration, Alameda, Calif.).
Assessment of bioluminescence versus optical density from S. pneumoniae
Tn4001 luxABCDE transposants. A single bioluminescent colony of S. pneu-
moniae was inoculated in 10 ml of BHI medium. Three hundred microliters of
overnight culture was inoculated in 30 ml of BHI and grown at 37°C in 5% CO2.
At 1-h intervals, both the optical density (OD) and the number of relative light
units (RLU) from a 1-ml culture volume were determined. The curves of RLU
versus OD at 600 nm (OD600) were plotted.
Transformation of clinical S. pneumoniae using natural competence. Chromo-
somal DNA from highly bioluminescent S. pneumoniae D39 Tn4001 luxABCDE
Kmr was used for natural transformation of several clinical isolates and prepared
as described previously (24). S. pneumoniae clinical isolates were grown in 10 ml
of BHI supplemented with 5% horse serum until the OD600 reached 0.1 to 0.15.
FIG. 1. Construction of plasmid pAUL-A Tn4001 luxABCDE Kmr.
For details, see Materials and Methods. IR, inverted repeat; EmR,
erythromycin resistance gene; tnp, transposase gene; TT, transcription
terminator; MCS, multiple cloning site.
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The culture was diluted 1:100 in 10 ml of warmed BHI supplemented with
5% horse serum containing CSP1 (EMRLSKFFRDFILQRKK) (15) or CSP2
(EMRISRIILDFLFLRKK) (30) and incubated for 20 min. One microgram of
the above chromosomal DNA was added to 500 ml of competent cells, and the
mixture was incubated for another 3 h. The transformation mix was then plated
on chocolate agar plates containing kanamycin at 400 mg/ml and incubated for
48 h. Colonies arising were screened for bioluminescence using an ICCD camera.
Southern blot analysis of S. pneumoniae Tn4001 luxABCDE Kmr chromosomal
DNA. To examine the integration of Tn4001 luxABCDE Kmr into the S. pneu-
moniae chromosome, Southern blot analysis was conducted according to the
manufacturer’s instructions (Alkphos direct labeling kit; Amersham Pharmacia
Biotech, Piscataway, N.J.). Chromosomal DNA from both D39 and clinical
isolates of S. pneumoniae Tn4001 luxABCDE Kmr were digested with a number
of restriction enzymes. These digestions were run on an agarose gel, and the
DNA was blotted onto a nitrocellulose filter and probed. The probe used to
hybridize to the target locus was a PCR-amplified luxA fragment amplified from
pSK luxAB using primers XAF3 (59 CCC CGG ATC CTG CAG ATG AAG
CAA GAG GAG GAC TCT CTA TG 39) and XAR (59 GGC GGA TCC GTC
GAC TTA ATA TAA TAG CGA ACG TTG 39) as described previously (11).
Inverse PCR. The genomic DNA sequence lying upstream of each Tn4001
luxABCDE Kmr integration site was obtained by inverse PCR (27). Chromo-
somal DNA from S. pneumoniae Tn4001 luxABCDE Kmr was digested with a
number of different restriction enzymes (both 4- and 6-bp recognition enzymes)
and self-ligated. The upstream region was PCR amplified using primers R2 (59
CGT TTC ATT ACC TCT GTT TGA G 39) and XBF (59 GGG AAT TCT CGA
GGA GGA GAG AAA GAA ATG AAA TTT GGA 39). Resulting PCR prod-
ucts were purified (PCR purification kit; Qiagen) and directly sequenced using
primer R2.
Monitoring bioluminescent pneumococcal infections in the lungs, and nasal
passaging in live mice. Exponential cultures of S. pneumoniae grown at 37°C in
BHI were pelleted and then resuspended in fresh BHI broth. Bacterial concen-
trations were estimated spectrophotometrically by absorbance at 600 nm and
adjusted to approximately 107 CFU/ml by dilution BHI. Cell numbers were
verified by plating dilutions of inoculum onto BHI agar.
Pneumococci were introduced into the lungs of mice (BALB/c females, 8 to 11
weeks old) by either direct intratracheal inoculation or intranasal administration.
The animals were anesthetized with ketamine (100 mg/ml) and xylazine (20
mg/ml), mixed at a 4:1 (vol/vol) ratio just before use. The anesthesia mixture was
injected intramuscularly into the right hamstring muscle at a dose of 100 mg of
ketamine/kg of body weight. After anesthesia was established, the mice were
inoculated with approximately 106 CFU in a total volume of 20 ml, using a
25-gauge ball-tipped gavage needle. Mice were held in vertical suspension for 10
min after inoculation to facilitate deep penetration of the inoculum. Alterna-
tively, mice were infected intranasally with approximately 106 CFU by placing 20
ml of bacterial suspension on the nares and allowing the mice to inhale the
inoculum. In the antibiotic studies, mice were treated with amoxicillin at 1 or 5
mg/kg, given subcutaneously at 0, 18, 24, and 42 h postinfection.
Mice were imaged for a maximum of 5 min at a number of time points
postinfection using an IVIS CCD camera (Xenogen Corporation). Total photon
emission from selected and defined areas within the images of each mouse was
quantified using the LivingImage software package (Xenogen Corporation). The
photon signal from the thorax was quantified from the ventral image of each
mouse.
Extraction and quantification of bacteria from lungs and nasal passages of
mice. After the final imaging time point, mice were sacrificed, and the infected
lung tissue was surgically removed and weighed. Both lungs were homogenized
together in 500 ml of BHI in a loose Dounce homogenizer. The suspension was
serially diluted in BHI and plated in duplicate onto BHI agar. Bacterial burden
was estimated from the number of CFU per gram of lung tissue.
The bacterial load present in the nasal passage of the mice was obtained by
washing approximately 0.25 ml of saline through the trachea and collecting the
first 0.1 ml of nasal wash as it exited the nares, as described previously (19, 37).
RESULTS
Both lux and Kmr genes are silent on pAUL-A in S. pneu-
moniae. Although the luxABCDE Kmr operon inserted in
pAUL-A is flanked on both sides by strong transcriptional
terminator sequences (Fig. 1), which should act to silence gene
expression (6), we found the regulation of this plasmid-located
operon to differ between E. coli and S. pneumoniae. E. coli
transformed with pAUL-A Tn4001 luxABCDE Kmr was uni-
formly bioluminescent, kanamycin resistant, and erythromycin
resistant (100% of all transformants initially selected on eryth-
romycin). Since the transformation frequency of these cells was
similar to that of E. coli transformed with the empty pAUL-A
plasmid (approximately 500 CFU/mg of DNA), and pAUL-A
Tn4001 luxABCDE Kmr DNA could be readily extracted from
the transformants by standard plasmid isolation procedures, it
is unlikely that lux Kmr gene expression is due to integration of
the plasmid into the E. coli chromosome. The more probable
explanation for this gene activity is that the luxABCDE Kmr
operon is expressed on pAUL-A in E. coli despite the lack of
any apparent promoter upstream of these genes.
In contrast to the plasmid gene expression found in E. coli,
in S. pneumoniae the plasmid-located luxABCDE Kmr operon
was silent. S. pneumoniae transformants containing pAUL-A
Tn4001 luxABCDE Kmr were dark (nonbioluminescent) when
selected on chocolate plates containing erythromycin (0.3 mg/
ml). Furthermore, the growth rate of an exponentially dividing
culture of such a transformant was dramatically inhibited by
the addition of kanamycin at concentrations of 400 mg/ml and
higher. However, after several hours in the presence of kana-
mycin, the growth of the pneumococcal culture reestablished
itself at a rate similar to that found prior to the addition of this
antibiotic. Moreover, a low level of bioluminescence could be
recorded from the latter culture. Together, these data indicate
that a subpopulation of the original culture, one in which the
luxABCDE Kmr operon was induced, had been selected.
Promoter strength can be selected for by varying the kana-
mycin concentration in the medium during isolation of chro-
mosomal integrants. S. pneumoniae pAUL-A Tn4001 luxABCDE
Kmr plated at 103 CFU on chocolate agar plates containing
increasing concentrations of kanamycin (400 to 1,000 mg/ml)
gave decreasing numbers of colonies. In comparison, the same
density of cells plated on chocolate plates without kanamycin
resulted in approximately 1,000 CFU. Although increasing
the concentration of kanamycin in the medium gave rise to
fewer transformants, the proportion of colonies producing
higher levels of bioluminescence was found to increase (Fig. 2).
This indicates that increasing the concentration of kanamycin
in the medium results in the selection of fusions with stronger
promoters upstream of the luxABCDE Kmr operon. Even in
the absence of kanamycin selection (screening on blank choc-
olate plates), approximately 3% of the 1,000 or so colonies
were bioluminescent. This level of transposition seen in S.
pneumoniae was significantly higher (approximately 1,000-fold)
than that observed in studies involving pAUL-A Tn4001
luxABCDE Kmr in Staphylococcus aureus and Listeria monocy-
togenes (data not shown).
Tn4001 luxABCDE Kmr is randomly inserted into the chro-
mosome of S. pneumoniae and stably maintained. One thou-
sand bioluminescent, kanamycin-resistant S. pneumoniae D39
colonies were patched in duplicate onto chocolate plates con-
taining either erythromycin (0.3 mg/ml) or kanamycin (400
mg/ml). All but 20 colonies grew on both antibiotics, indicating
that the vast majority (98%) of the transformants had the
entire pAUL-A Tn4001 luxABCDE Kmr DNA integrated into
their chromosome. Southern blot analysis of genomic DNA
from 10 kanamycin- and erythromycin-resistant colonies con-
firmed that the whole plasmid had integrated into the S. pneu-
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moniae chromosome. In contrast, Southern blot analysis of
genomic DNA from 10 kanamycin-resistant erythromycin-sen-
sitive colonies showed that all 10 isolates were true trans-
posants and that each strain contained only one copy of the lux
transposon construct (data not shown). Furthermore, sequenc-
ing of the chromosomal lux fusion junctions (gained by inverse
PCR) of each of these transposants confirmed that all 10 in-
tegration sites were unique, confirming that Tn4001 transpo-
sition in S. pneumoniae occurs randomly (data not shown).
Four clinical isolates of S. pneumoniae were naturally trans-
formed with chromosomal DNA of a highly bioluminescent,
kanamycin-resistant, erythromycin-sensitive D39 transposant,
designated Xen 7. The transformation efficiency varied from 50
to 500 CFU/mg of Xen 7 chromosomal DNA. These transfor-
mants were named Xen 9, Xen 10, Xen 11, and Xen 12,
corresponding to strains HUSTMBIG, A66.1, EF3030, and
140301, respectively. To test whether the transposon was stably
maintained at its original integration site, Xen 9 and Xen 10
were cultured in BHI medium with or without kanamycin for 2
weeks at 37°C, diluting the cells 1:1,000 into fresh medium
every 12 h. Chromosomal DNAs were prepared on days 0, 3, 7,
10, and 14, and the ratio of kanamycin-resistant colonies to
total CFU was examined at the same times. Tn4001 luxABCDE
Kmr in both Xen 9 and Xen 10 was found to be 100% stable,
so that after 14 days of continuous culturing without antibiotic
selection, all CFU were bioluminescent and the locations of
the transposons in both strains remained the same and at
single copy (data not shown).
Photon emission from bioluminescent S. pneumoniae de-
creases dramatically as cells enter stationary phase. To eval-
uate the level of bioluminescence in the different strains of S.
pneumoniae during growth, RLU were recorded from strain
D39 (Xen 7) and the four clinical isolates (Xen 9 to 12) during
in vitro growth using an ICCD camera and Xenogen’s Living-
Image software. As Fig. 3 shows, in all five strains the photon
counts increased during exponential growth and then de-
creased dramatically to about 5% of their peak values once the
bacteria entered stationary phase. For strain Xen 11, the peak
photon counts were less than those recorded for the other
strains, which might reflect strain variation. This reasoning is
supported by the observation that EF3030 Xen 11 showed a
different hybridization pattern in a Southern blot analysis than
the donor strain Xen 7 and the other transformed strains, Xen
9, Xen 10, and Xen 12. Despite these differences, inverse PCR
showed that the transposon in Xen 11 was integrated at the
same site as it was in the other strains (data not shown). This
integration site is located in the second open reading frame
(ORF) of a possible two-gene operon (www.tigr.org, contig
3836, bases 1719329 to 1720455). The sequence of this ORF
has no significant similarity at the DNA or protein level to any
sequence in the NCBI database.
To investigate whether the stationary-phase phenomenon
described above was due to the regulation of one specific
promoter or was a true consequence of the growth phase of S.
pneumoniae, 10 bioluminescent D39 transposants were ran-
domly picked from a chocolate plate supplemented with kana-
mycin and their RLU were measured during growth. In all the
cases, the RLU were significantly reduced to basal levels when
the stationary phase was reached (data not shown), suggesting
that the reduction of photon emission was a stationary-phase
phenomenon in S. pneumoniae.
Bioluminescent S. pneumoniae A66.1 Xen 10 can be used to
accurately monitor pneumococcal drug efficacy studies in vivo
in live animals. Initial experiments with S. pneumoniae D39
Xen 7 showed that this strain performed poorly in animal
respiratory infection studies. Thus, strains HUSTMBIG,
A66.1, EF3030, and 140301 were made bioluminescent as de-
scribed above and tested in both mouse lung and nasopharyn-
geal models. A66.1 Xen 10 was found to perform best in the
mouse pneumococcal lung model (see Fig. 4 and 5), whereas
HUSTMBIG Xen 9 and EF3030 Xen 11 performed best in the
nasopharyngeal model (see Fig. 6). Similar to D39 Xen 7,
strain 140301 Xen 12 did not perform well in either model.
Comparison of S. pneumoniae D39, EF3030, and HUSTMBIG
(both parental and bioluminescent derivatives) revealed that
the latter two clinical isolates were far superior to D39 in
colonizing the nasopharynx of mice. Recovery of bacteria from
nasal washes of infected mice was 100- to 1,000-fold higher
from both EF3030 and HUSTMBIG than from D39. In addi-
tion, no statistical difference could be seen between the parent
and bioluminescent derivative for any strain, suggesting that
the insertion of the lux transposon did not alter these virulence
characteristics (data not shown).
Since A66.1 Xen 10 performed best in the mouse pneumo-
coccal lung model, this strain was selected to test in a drug
efficacy study. Twelve mice were inoculated with approximately
106 CFU of S. pneumoniae A66.1 Xen 10. The mice were
divided into three groups of four animals each, and two of
these groups were treated with amoxicillin at 1 or 5 mg/kg; the
third group of animals were left untreated as controls. Figure
4 shows an example of the type of visual data seen in vivo (one
animal from each group of four) using this bioluminescent S.
pneumoniae strain. In the untreated group of animals, a strong
bioluminescent signal could be detected from the thorax of
FIG. 2. Effects of kanamycin concentration on selection of pro-
moter strength. S. pneumoniae D39 Xen 7 was grown to mid-exponen-
tial phase, and 103 CFU were plated on chocolate agar plates supple-
mented with various concentrations of kanamycin. Open squares, total
CFU on the plates; solid circles, ratio of light to total CFU. The
numbers of CFU are the averages for five plates at each kanamycin
concentration.
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three of the four mice by 20 h, indicating that three of the mice
had an established pneumococcal lung infection. These ani-
mals all had ruffled fur and appeared ill, whereas the fourth
control animal, showing no bioluminescent signal, appeared
healthy, indicating that it was uninfected (see below). Over the
next 28 h (up to 48 h postinoculation), the three infected
control animals showed increasing bioluminescent signals from
their lungs (Fig. 5), the mouse with the highest signal at 26 h
dying overnight before the 44-h imaging time point. By 48 h
postinoculation, at least one of the two remaining infected
mice appeared extremely ill, with both animals having intense
bioluminescent signals.
All eight of the amoxicillin (1 and 5 mg/kg groups)-treated
mice appeared well at the 20-h imaging time point compared
to the control group. Three of the four animals treated with
amoxicillin (1 mg/kg) had a bioluminescent signal 20 h post-
inoculation. None of the animals treated with amoxicillin (5
mg/kg) had a significant bioluminescent signal at the 20-h time
point. In comparison, the untreated control animals developed
a bioluminescent signal that was several-thousand-fold greater
than that of either group of amoxicillin-treated animals (Fig.
5).
Plating of lung tissue extracts following sacrifice of each of
the mice after the 48-h imaging time point showed that only
the two untreated animals with strong bioluminescent signals
had large numbers of pneumococci present (the third mouse
with a strong bioluminescent signal had died prior to this time
point). One of these animals, with a bioluminescent signal of
443,100 RLU, had 2 3 109 CFU/g of tissue. No bacteria could
be recovered from the untreated mouse that did not have a
bioluminescent signal, supporting the assumption that a pneu-
mococcal infection had not been established in this host. The
highest number of pneumococci to be isolated from an amoxi-
cillin-treated animal was 300 CFU/g of tissue, with four of the
eight animals showing no bacteria present (Fig. 6).
All pneumococci recovered from long-term mouse naso-
pharyngeal infections are bioluminescent. S. pneumoniae
HUSTMBIG Xen 9 and EF3030 Xen 11 recovered from nasal
washes performed on mice with 7-day pneumococcal nasopha-
ryngeal infections (i.e., from the mice shown in Fig. 6) were
shown to be 100% bioluminescent.
DISCUSSION
Bioluminescent S. pneumoniae D39 was initially generated
using plasmid pDL289 (4), carrying the modified luxABCDE
FIG. 3. RLU emitted by bioluminescent S. pneumoniae strains during in vitro growth. Three hundred microliters of overnight culture was
inoculated into 30 ml of BHI and grown at 37°C in 5% CO2. At 1-h intervals, both the OD600 (open circles) and the number of RLU 3 10
6 (solid
squares) from a 1-ml culture volume were determined for each of the strains. The experiment was repeated three times for each strain.
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construct (11). However, as with Staphylococcus aureus con-
taining pMK4 luxABCDE constructs (11), plasmid loss in the
absence of antibiotic selection from these S. pneumoniae cells
was unacceptably high in animal studies lasting longer than
48 h (unpublished data). In order to stabilize the biolumines-
cence emitted from the pneumococcal cells, we integrated the
luxABCDE cassette into the bacterium’s chromosome. Strains
of S. pneumoniae are readily transformable by natural compe-
tence procedures to facilitate homologous recombination of
gene fusions, as has previously been shown using reporter
genes such as lacZ (28). However, studies conducted by our
group with S. aureus showed that it was difficult to predict how
a particular luxABCDE fusion would behave on the chromo-
some. Thus, in order to generate a pool of chromosomal lux
fusions that could be screened on the basis of their biolumi-
nescent signal, we investigated the possibility of building a
gram-positive lux transposon.
Several gram-positive transposons were considered as can-
didates for integration of the luxABCDE cassette, including
Tn917 and the conjugative transposon Tn916 (26, 36). How-
ever, due to its small size, broad host range, and genetic ame-
nability on plasmid pMGC57 (5, 21), the composite-type trans-
FIG. 4. Bioluminescent S. pneumoniae A66.1 Xen 10 in a mouse pneumococcal lung model, with and without antibiotic treatment. Twelve mice
were inoculated with approximately 106 CFU of S. pneumoniae A66.1 Xen 10. The mice were divided into three groups of four animals each, and
two of these groups were treated with amoxicillin at 1 or 5 mg/kg given subcutaneously at 0, 18, 24, and 42 h postinfection; the third group of
animals were left untreated as controls. Mice were imaged using an IVIS CCD camera (Xenogen Corporation) at the indicated time points
postinfection. Total photon emission from the ventral thoracic region of each mouse (areas inside the yellow circle) was quantified using the
LivingImage software package (Xenogen Corporation). Imaging time was 5 min unless otherwise shown.
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poson Tn4001 was selected. This transposon has been used for
the random mutagenesis of several mycoplasmas and a range
of gram-positive bacteria (8, 10, 20–23, 32), including Strepto-
coccus pyogenes and Streptococcus gordonii (20, 21). As far as
we are aware, this is the first instance in which Tn4001 has been
used for the mutagenesis of S. pneumoniae.
Prior studies have shown that Tn4001 chooses its targets for
insertion with a high degree of randomness and that this trans-
poson is highly stable in streptococci (20, 21). Mutagenesis of
S. pyogenes with Tn4001.spc was shown to be extremely effi-
cient using the suicide plasmid pMGC57-spc, with transposi-
tion frequencies of between 103 and 106/mg of DNA, depend-
ing on the S. pyogenes host strain used. Unfortunately, we were
unable to achieve such transposition frequencies in strains of S.
pneumoniae using pMGC57-spc. This may be due in part to low
plasmid transformation efficiencies achieved by electropora-
tion of this bacterium (approximately 102 transformants/mg of
pDL289 DNA). Thus, in order to stably maintain the Tn4001
luxABCDE Kmr construct in S. pneumoniae and so increase the
efficiency of transposition, we chose to move this construct
onto the gram-positive/negative temperature-sensitive plasmid
pAUL-A (6).
Transposition of Tn4001 luxABCDE Kmr in S. pneumoniae
D39 occurred at a frequency of approximately 1023. However,
the vast majority (98%) of these transformants were bacteria
with the entire pAUL-A construct incorporated onto their
chromosome, reducing the true frequency of Tn4001 transpo-
sition to approximately 1025. In contrast, transposition of
Tn4001 luxABCDE Kmr in both S. aureus and L. monocyto-
genes occurred at a frequency of between 1025 and 1026, and
all transformants tested were erythromycin sensitive, indicating
loss of the pAUL-A backbone (our unpublished data). At
present it is not known why the entire pAUL-A Tn4001
luxABCDE Kmr plasmid should integrate into the chromo-
some of S. pneumoniae D39 at such a high frequency, espe-
cially when plasmid integration does not appear to occur in
either S. aureus or L. monocytogenes, and Lyon et al. (21)
showed that this phenomenon occurs at a frequency of ,0.1%
using pMGC57-spc in S. pyogenes.
Comparing RLU to CFU in S. pneumoniae cultures showed
that photon emissions decreased dramatically when the bacte-
rial cells entered stationary phase (Fig. 3). This steep decline in
bioluminescence was universal for all S. pneumoniae lux trans-
formants tested, including pDL289 luxABCDE transformants
(data not shown), showing that this phenomenon was not
caused by reduced transcription from a specific promoter. Pre-
vious studies in both gram-positive and gram-negative bacteria
have shown that bioluminescence decreases once the cells en-
ter stationary phase (14, 25, 34, 35; unpublished data). How-
ever, this light reduction is usually gradual and reflects a slow
decrease in the metabolic activity of the cell (25, 34). It is
possible that the sharp decrease in bioluminescence seen from
S. pneumoniae entering stationary phase is due to a decrease of
reduced flavin mononucleotide to feed the bioluminescent re-
action. Reduced flavin mononucleotide is generated in aerobic
bacteria via components of the electron transport chain. How-
ever, S. pneumoniae is a facultative anaerobe that lacks an
intact respiratory chain and as such may generate these com-
FIG. 5. Graphic representation of mean thoracic bioluminescence (RLU) from the pneumococcus-infected mice, untreated and treated with
amoxicillin, shown in Fig. 4. Each point represents the average bioluminescence from all surviving mice in each treatment group (starting with four
mice in each group). E, untreated animals; {, treated (5 mg/kg) animals; h, treated (1 mg/kg) animals. The average CFU per gram of lung tissue
for each group of animals at 48 h (time of sacrifice) is given in parentheses.
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ponents less efficiently (17, 29). Similar sharp falls in biolumi-
nescence in stationary-phase cultures have been reported for
luxAB constructs in the closely related bacterium Lactococcus
lactis (35). Interestingly, this phenomenon does not appear to
have a significant effect in vivo in living animals (Fig. 4, 5, and
6).
Initial studies with bioluminescent S. pneumoniae D39
(mostly Xen 7) showed that it was possible to monitor pneu-
mococcal cells in vivo in a mouse thigh model (unpublished
data). However, this particular strain (D39) gave little to no
signal when inoculated into the animal’s lungs. In contrast to
D39, S. pneumoniae A66.1 Xen 10 performed extremely well in
the lungs of mice (Fig. 4 and 5). Bioluminescence could be
detected for at least 48 h, indicating that this strain can be used
for in vivo pneumococcal drug efficacy studies. The strains
HUSTMBIG Xen 9 and EF3030 Xen 11, which performed
best in the mouse nasopharyngeal model (Fig. 6), may prove to
be valuable candidates for vaccination studies due to their
longevity of colonization of the nasal passage.
Both of the pneumococcal animal models used in this study
demonstrate some of the significant advantages that real-time
photonic imaging offers over conventional methods for moni-
toring and combating bacterial disease in animals. Not only
does this approach reduce the time and cost of conducting such
experiments, but it also considerably reduces the number of
animals used (7, 11). Furthermore, because bioluminescent
imaging allows the same group of animals to be monitored
over time, animal-to-animal variations are overcome by includ-
ing the zero time point as an internal control. In addition to
this procedure improving biostatistics, several parameters of
drug efficacy and pharmacokinetics can be more accurately
measured in the discovery and development stages of drug
evaluation.
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